ATAI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

275.00K

-5600%

-0.117

-51.19%

107.00K

-93.12%

-0.112

-25.33%

107.00K

-85.12%

-0.138

-1.43%

Estimates Revision

The market is revising Upward the revenue expectations for Atai Beckley N.V. (ATAI) for FY2025, with the revenue forecasts being adjusted by 34.1% over the past three months. During the same period, the stock price has changed by -10.22%.

Revenue Estimates for FY2025

Revise Upward

+34.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.82%

In Past 3 Month

Stock Price

Go Down

-10.22%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast ATAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATAI is 12.71 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.175

Low

10.00

Averages

12.71

High

16.00

Current: 4.175

Low

10.00

Averages

12.71

High

16.00

Berenberg

Positive -> Buy

upgrade

$12

2025-10-24

Reason

Berenberg

Price Target

$12

2025-10-24

upgrade

Positive -> Buy

Reason

Berenberg placed a Buy rating on Atai Life Sciences with a $12 price target saying the company has made "exceptional progress" since its initiation with a Positive rating six months ago. Atai has a building pipeline momentum, its funding is secured, Phase 3 entry for its lead programmed is due in the first half 2026, and several more catalysts are expected over the next 12 months, the analyst tells investors in a research note. Berenberg sees the stock's momentum continuing.

Canaccord

Buy

maintain

$11 -> $14

2025-10-22

Reason

Canaccord

Price Target

$11 -> $14

2025-10-22

maintain

Buy

Reason

Canaccord raised the firm's price target on Atai Life Sciences to $14 from $11 and keeps a Buy rating on the shares. The firm noted their merger with privatley held Beckley is on track to close in Q4 while recently announcing the FDA granted breakthrough therapy designation (BTD) to Beckley's BPL-003 (intranasal mebufotenin), which had solid Phase 2 data for treatment-resistant depression.

Jefferies

Buy

maintain

$7 -> $10

2025-10-17

Reason

Jefferies

Price Target

$7 -> $10

2025-10-17

maintain

Buy

Reason

Jefferies raised the firm's price target on Atai Life Sciences to $10 from $7 and keeps a Buy rating on the shares. The ATAI-Beckley story "becomes more attractive" with the FDA granting a breakthrough designation to BPL-003, according to the analyst, who expects Atai to meet with the FDA to discuss Phase 3 design and regulatory strategy in Q4. The firm, which views BPL-003 as differentiated from other psychedelics due to single-dose durability and an in-clinic dosing paradigm, notes that its analysis shows a 72%-plus approval rate for drugs with BTD, so it argues the drug's prospects "could be more favorable" than current Street thinking.

Oppenheimer

Outperform

maintain

$14 -> $16

2025-08-01

Reason

Oppenheimer

Price Target

$14 -> $16

2025-08-01

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Atai Life Sciences to $16 from $14 and keeps an Outperform rating on the shares as recent dynamics bode well for BPL-003. As large cap players vie for leadership in neuroscience, psychiatry is increasingly in focus while acquisitions of smaller players are an important source of innovation, Oppenheimer notes.

H.C. Wainwright

Patrick Trucchio

Buy

maintain

$10 -> $15

2025-07-30

Reason

H.C. Wainwright

Patrick Trucchio

Price Target

$10 -> $15

2025-07-30

maintain

Buy

Reason

H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Atai Life Sciences to $15 from $10 and keeps a Buy rating on the shares. The firm remains bullish on Atai despite the Phase 2b trial evaluating inidascamine in patients with cognitive impairment associated with schizophrenia missing the primary endpoint. In a follow-up call, management reiterated the company focus on the company's wholly-owned psychedelics pipeline, including BPL-003, which has continued to exceed expectations, the analyst tells investors in a research note. H.C. Wainwright cites Atai's focus on its "most promising near-term asset" for the target increase.

Oppenheimer

Outperform

initiated

$14

2025-07-29

Reason

Oppenheimer

Price Target

$14

2025-07-29

initiated

Outperform

Reason

Oppenheimer initiated coverage of Atai Life Sciences with an Outperform rating and $14 price target. The firm says Atai is the leading the psychedelic revolution within neuropsychiatry. The market opportunity is underappreciated considering 10M patients could benefit from alternative approaches, the analyst tells investors in a research note. Atai's Phase 2b data for BPL-003 solidify a "transformational approach," the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Atai Beckley NV (ATAI.O) is -8.54, compared to its 5-year average forward P/E of -5.01. For a more detailed relative valuation and DCF analysis to assess Atai Beckley NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.01

Current PE

-8.54

Overvalued PE

-0.85

Undervalued PE

-9.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.84

Current EV/EBITDA

-10.72

Overvalued EV/EBITDA

1.47

Undervalued EV/EBITDA

-9.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

23870.23

Current PS

2614.24

Overvalued PS

82266.40

Undervalued PS

-34525.94

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 653.97% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 121.2% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 653.97% over the last month.

Sold

Bought

ATAI News & Events

Events Timeline

No data

News

3.5

12-11Newsfilter

AtaiBeckley Secures New Patent for EMP-01, Ensuring Exclusivity Until 2043

5.0

11-20Newsfilter

Enhanced Strengthens Executive Leadership Team and Board of Directors

1.0

11-13Newsfilter

AtaiBeckley to Attend the Jefferies Global Healthcare Conference in London

People Also Watch

Frequently Asked Questions

What is Atai Beckley NV (ATAI) stock price today?

The current price of ATAI is 4.175 USD — it has decreased -2.68 % in the last trading day.

What is Atai Beckley NV (ATAI)'s business?

Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

What is the price predicton of ATAI Stock?

What is Atai Beckley NV (ATAI)'s revenue for the last quarter?

Atai Beckley NV revenue for the last quarter amounts to 749.00K USD, increased 1772.50 % YoY.

What is Atai Beckley NV (ATAI)'s earnings per share (EPS) for the last quarter?

Atai Beckley NV. EPS for the last quarter amounts to -0.28 USD, increased 75.00 % YoY.

What changes have occurred in the market's expectations for Atai Beckley NV (ATAI)'s fundamentals?

How many employees does Atai Beckley NV (ATAI). have?

Atai Beckley NV (ATAI) has 54 emplpoyees as of December 15 2025.

What is Atai Beckley NV (ATAI) market cap?

Today ATAI has the market capitalization of 1.56B USD.